皓宸医疗（002622）2月3日主力资金净买入488.56万元

Core Viewpoint - Haocen Medical (002622) has experienced a significant decline in both revenue and net profit for the first three quarters of 2025, indicating potential challenges in its business operations and financial health [2]. Financial Performance - For the first three quarters of 2025, Haocen Medical reported a main revenue of 527 million yuan, a year-on-year decrease of 17.03% [2]. - The net profit attributable to shareholders was -26.41 million yuan, reflecting a year-on-year decline of 295.68% [2]. - The net profit after deducting non-recurring gains and losses was -24.52 million yuan, down 288.77% year-on-year [2]. - In Q3 2025, the company recorded a single-quarter main revenue of 213 million yuan, a decrease of 15.72% year-on-year [2]. - The single-quarter net profit attributable to shareholders was -2.66 million yuan, a decline of 120.54% year-on-year [2]. - The single-quarter net profit after deducting non-recurring gains and losses was -966,000 yuan, down 107.53% year-on-year [2]. - The company's debt ratio stands at 71.72%, with investment income of 2.67 million yuan and financial expenses of 31.15 million yuan [2]. - The gross profit margin is reported at 47.72% [2]. Stock Performance - As of February 3, 2026, Haocen Medical's stock closed at 2.98 yuan, down 1.97% with a turnover rate of 3.55% [1]. - The trading volume was 298,500 hands, with a total transaction amount of 89.67 million yuan [1]. - On February 3, the net inflow of main funds was 4.89 million yuan, accounting for 5.45% of the total transaction amount [1]. - Retail investors experienced a net outflow of 2.66 million yuan, representing 2.97% of the total transaction amount [1].